Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - dabigatran etexilate mesylate 172.95mg equivalent to dabigatran etexilate 150 mg;  ;   - capsule - 150 mg - active: dabigatran etexilate mesylate 172.95mg equivalent to dabigatran etexilate 150 mg     excipient: acacia dimeticone hyprolose hypromellose hpmc capsule size 0 (tt70-14-2-4) purified talc tartaric acid tekprint black sw-9008 - prevention of venous thromboembolic events in patients who have undergone major orthopaedic surgery.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - dabigatran etexilate mesylate 86.48mg equivalent to dabigatran etexilate 75 mg;  ;   - capsule - 75 mg - active: dabigatran etexilate mesylate 86.48mg equivalent to dabigatran etexilate 75 mg     excipient: acacia dimeticone hyprolose hypromellose hpmc capsule size 2 - (tt70-14-2-3) purified talc tartaric acid tekprint black sw-9008 - prevention of venous thromboembolic events in patients who have undergone major orthopaedic surgery.

Irska - engleski - HPRA (Health Products Regulatory Authority)

peckforton pharmaceuticals ltd - dicyclomine hydrochloride aluminium hydroxide gel magnesium oxidum leve dimeticone, activated - oral suspension - per cent

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nizatidine, quantity: 150 mg - capsule, hard - excipient ingredients: dimeticone 350; maize starch; pregelatinised maize starch; magnesium stearate; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - tazac is indicated for up to 8 weeks for the treatment of active duodenal ulcer. in most patients, the ulcer will heal within 4 weeks. tazac is also indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of active duodenal ulcer. continuous therapy with nizatidine for longer than 1 year has not been studied. tazac is indicated for up to 8 weeks for the treatment of benign gastric ulcer. tazac is indicated for up to 12 weeks for the treatment of oesophagitis, including erosive and ulcerative oesophagitis and associated heartburn due to reflux.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nizatidine, quantity: 150 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; dimeticone 350; maize starch; magnesium stearate; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - nizac is indicated for up to 8 weeks for the treatment of active duodenal ulcer. in most patients, the ulcer will heal within 4 weeks. nizac is also indicated for maintenance therapy of duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. continuous therapy with nizatidine for longer than 1 year has not been studied. nizac is indicated for up to 8 weeks for the treatment of benign gastric ulcer. nizac is indicated for up to 12 weeks for the treatment of oesophagitis, including erosive and ulcerative oesophagitis and associated heartburn due to reflux.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 114.3 mg (equivalent: atomoxetine, qty 114.3 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; sorbitan monolaurate; iron oxide red; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 91.44 mg (equivalent: atomoxetine, qty 91.44 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; sorbitan monolaurate; iron oxide red; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 68.58 mg (equivalent: atomoxetine, qty 68.58 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; iron oxide yellow; sorbitan monolaurate; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 45.72 mg (equivalent: atomoxetine, qty 40 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - atomoxetine hydrochloride, quantity: 28.58 mg (equivalent: atomoxetine, qty 25 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.